Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PN-30X
- Development stage
- Preclinical
- Lead developer
- Paean Biotechnology
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
PN-30X is a preclinical-stage therapeutic candidate developed by Paean Biotechnology, utilizing a modified mitochondrial transplantation platform. The drug leverages two proprietary technologies: CAR-Mito (Chimeric Antigen Receptor-Mitochondria) and AMDC (Artificial Mitochondrial Delivery Carrier). PN-30X is designed to deliver or augment mitochondria within target cells to modulate cellular bioenergetics and function. It is currently being investigated for the treatment of various cancers and central nervous system (CNS) diseases, where mitochondrial dysfunction or metabolic reprogramming plays a critical role in pathogenesis.
Beyond the preview
Go deeper on PN-30X.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PN-30X.